Evaluation of the in vitro activity of levofloxacin and moxifloxacin tested against Stenotrophomonas maltophilia:: can moxifloxacin activity be predicted by levofloxacin MIC results?

被引：0
|
作者：
Gales, A.
Jones, R.
Janechek, M.
Sader, H.
机构：
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2007年 / 29卷
关键词：
D O I：
10.1016/S0924-8579(07)71476-0
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
下载
收藏
页码：S461 / S462
页数：2
相关论文
共 50 条
  • [31] Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia
    Valdezate, S
    Vindel, A
    Baquero, F
    Cantón, R
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (12) : 908 - 911
  • [32] In vitro activity of moxifloxacin against local bacterial isolates
    Ling, ML
    Tan, PL
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2001, 30 (06) : 607 - 610
  • [33] Bactericidal Activity of Ceragenin in Combination with Ceftazidime, Levofloxacin, Co-Trimoxazole, and Colistin against the Opportunistic Pathogen Stenotrophomonas maltophilia
    Paprocka, Paulina
    Mankowska, Angelika
    Sklodowski, Karol
    Krol, Grzegorz
    Wollny, Tomasz
    Lesiak, Agata
    Gluszek, Katarzyna
    Savage, Paul B.
    Durnas, Bonita
    Bucki, Robert
    PATHOGENS, 2022, 11 (06):
  • [34] In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics
    Schaumann, Reiner
    Janssen, Eva
    Funke, Matthias
    Stingu, Catalina S.
    Genzel, Gelimer H.
    Janssen, Martin
    Rodloff, Arne C.
    JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 62 : 576 - 581
  • [35] Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model
    Ba, BB
    Feghali, H
    Arpin, C
    Saux, MC
    Quentin, C
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) : 946 - 953
  • [36] A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia
    Wei, Chuanqi
    Ni, Wentao
    Cai, Xuejiu
    Cui, Junchang
    INFECTIOUS DISEASES, 2015, 47 (12) : 846 - 851
  • [37] In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
    Nakamura, Rio
    Oota, Merime
    Matsumoto, Shuhei
    Sato, Takafumi
    Yamano, Yoshinori
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
  • [38] Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model
    Allen, GP
    Kaatz, GW
    Rybak, MJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) : 2606 - 2614
  • [39] Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole
    Biagi, M.
    Tan, X.
    Wu, T.
    Jurkovic, M.
    Vialichka, A.
    Meyer, K.
    Mendes, R. E.
    Wenzler, E.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (02)
  • [40] In vitro activity of moxifloxacin against community respiratory pathogens in Qatar
    Elshafie, SS
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (03) : 309 - 310
12345